Figure 2.

Vesicular stomatitis virus (VSV) replication is poor in B16-F10 tumors and leads to no efficacy. (a) C57BL/6 mice-bearing B16-F10 subcutaneous tumors were injected intravenously (i.v.) with 5 × 10⁸ plaque-forming unit (pfu) of VSV-Δ51. Two days later, mice were euthanized, and tumors were harvested and frozen. Sections were stained by immunohistochemistry (IHC) for VSV. (b) C57BL/6 mice-bearing B16-F10 subcutaneous tumors were injected three times a week starting on day 6 for a total of six doses of VSV-Δ51 i.v. Tumor area growth over time plotted for PBS (in black) and VSV-Δ51 treated (in red). N = 6 per group. (c) Kaplan–Meier survival analysis with statistics examined by log rank test where P > 0.2.